Click the icons below to search through Pioneer’s reports and documents.
|Date added||January 23, 2019|
|Category||Health Care, Health Care Policy (Federal), Health Care Policy (MA), Life Sciences, White Papers|
Date: January 24, 2019
Author: Dr. William Smith
As states continue to grapple with prescription drug costs, a new Pioneer Institute study lays out the key ethical, methodological and disease-specific questions policy makers should address before deciding whether to contract with the Institute for Clinical and Economic Review (ICER) to conduct cost effectiveness reviews used to make decisions about the purchase of medicines and other medical innovations.